Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
169 hedge funds and large institutions have $947M invested in Eagle Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 80 increasing their positions, 37 reducing their positions, and 36 closing their positions.
116% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 37
31% more call options, than puts
Call options by funds: $7.68M | Put options by funds: $5.85M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
3% less funds holding
Funds holding: 175 → 169 (-6)
22% less capital invested
Capital invested by funds: $1.21B → $947M (-$264M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$30.3M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$17.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.9M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$13.8M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$221M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$49.8M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$15.9M |
| 4 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$12.4M |
| 5 |
MCM
Matarin Capital Management
New York
|
-$8.16M |
EGRX Hedge Fund Activity: Q3 2017 in Review
169 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2017, worth a combined $947M — down 22% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of EGRX and 34 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 80 added.
The largest buyer was Park West Asset Management, adding an estimated $30.3M. The largest seller was ProQuest Associates IV, cutting an estimated $221M.
- 169 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2017, down from 175 in Q2 2017.
- Funds reported $947M of Eagle Pharmaceuticals, Inc. stock for Q3 2017, down 22% quarter-over-quarter.
- 34 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2017 and 36 closed out, a net change of -2 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2017 was Park West Asset Management, an estimated $30.3M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2017 was ProQuest Associates IV, an estimated $221M sold.
Based on aggregated 13F filings for Q3 2017.